3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Thrombocytopenia
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Interventions
Specimen Handling
273
Magnetic Resonance Spectroscopy
226
pembrolizumab
218
Carboplatin
174
Biopsy
164
Cisplatin
157
Nivolumab
155
Cyclophosphamide
139
Radiotherapy
121
Paclitaxel
120
Gemcitabine
113
durvalumab
90
Bevacizumab
89
Dexamethasone
82
Rituximab
81
Oxaliplatin
77
venetoclax
73
atezolizumab
70
Doxorubicin
70
Docetaxel
66
Radiosurgery
65
Fluorouracil
65
Ipilimumab
64
Capecitabine
64
Etoposide
62
Radiation
59
Prednisone
59
Cytarabine
59
Lenalidomide
56
fludarabine
53
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Tranexamic Acid
×
90 days
×
Clear all
NCT06599762
2026-04-22
MYELO-CAN:TXA
University of Manitoba
Phase 2
Recruiting
75 enrolled